← Evidence map

ArticleNeurology international2026

Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.

Michail Vikelis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group. | OpenQuestion